When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
GSK - ViiV and Janssen announce positive data on long-acting HIV doublet therapy
GlaxoSmithKline PLC
A Phase 3 clinical trial, ATLAS-2M, evaluating the combination of ViiV Healthcare's cabotegravir and Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceuticals' rilpivirine administered every two months showed it to be non-inferior (no worse than) to monthly dosing in adult patients with HIV-1 infection with suppressed viral loads who were not resistant to either drug.
More news on: Johnson & Johnson, GlaxoSmithKline plc, Pfizer Inc., Healthcare stocks news,